At 24 months, 67% of patients achieved a complete response (CR). In the 12 patients who completed 24 cycles, 75% of patients remained in remission at a median follow-up of 7 months following treatment discontinuation. “Ongoing correlative studies and longer follow-up will define which patient characteristics are associated with long remissions after time-limited therapy with acalabrutinib plus obinutuzumab. Per the Rai staging system, 4% of patients had low-risk disease, 39% had intermediate-risk disease, and 57% had high-risk disease. Bone marrow infiltration by CLL cells significantly decreased from a median of 84.2% at baseline to 0.1% after 24 cycles of therapy, and 4 patients achieved undetectable minimal residual disease.

Source: Washington Post July 25, 2024 13:09 UTC